盐酸坦洛新缓释胶囊 英国药典2011.doc

盐酸坦洛新缓释胶囊 英国药典2011.doc 英国药典2011 Prolonged-release Tamsulosin Capsules General Notices Prolonged-release Tamsulosin Capsules from different manufacturers, whilst complying with the requirements of the monograph, are not interchangeable unless otherwise justified and authorised. DEFINITION Prolonged-release Tamsulosin Capsules contain Tamsulosin Hydrochloride. They are formulated so that the medicament is released over a period of several hours. PRODUCTION A suitable dissolution test is carried out to demonstrate the appropriate release of Tamsulosin Hydrochloride. The dissolution profile reflects the in vivo performance which in turn is compatible with the dosage schedule recommended by the manufacturer. The capsules comply with the requirements stated under Capsules and with the following requirements. Content of tamsulosin hydrochloride, CHNOS,HCl 202825 95.0 to 105.0% of the stated amount. IDENTIFICATION A. In the Assay, the principal peak in the chromatogram obtained with solution (1) has the same retention time as that in the chromatogram obtained with solution (2). B. The light absorption of solution (1) obtained in the Assay, Appendix II B in the range 210 to 400 nm, exhibits a single maximum at 225 nm. TESTS Related substances Carry out the method for liquid chromatography, Appendix III D, using the following solutions. (1) Mix for at least 15 minutes with the aid of ultrasound and with intermittent shaking a quantity of the capsules containing 0.8 mg of Tamsulosin Hydrochloride with 10 ml of 1M methanolic hydrochloric acid and filter through a 0.7-µm glass fibre filter, to 1 volume of the filtrate add 4 volumes of 1M methanolic hydrochloric acid and filter through a 0.7-µm glass fibre filter. (2) Dilute 1 volume of solution (1) to 500 volumes with mobile phase. (3) 0.00032% w/v of tamsulosin hydrochloride impurity standard BPCRS in the mobile phase. (4) Dilute 1 volume of solution (2) to 4 volumes with mobile phase. CHROMATOGRAPHIC CONDITIONS (a) Use a stainless steel column (15 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 µm) (Nucleosil C18 100Å is suitable). (b) Use isocratic elution and the mobile phase described below. (c) Use a flow rate of 1.5 ml per minute. (d) Use a column temperature of 40?. (e) Use a detection wavelength of 225 nm. (f) Inject 20 µl of each solution. (g) Allow the chromatography to proceed for 40 minutes. MOBILE PHASE 300 volumes of acetonitrile mixed with 700 volumes of water containing 0.44% v/v perchloric acid and 0.15% w/v sodium hydroxide previously adjusted to pH 2.0 with 1M sodium hydroxide. SYSTEM SUITABILITY The test is not valid unless the chromatogram obtained with solution (3) closely resembles the chromatogram supplied with tamsulosin hydrochloride impurity standard BPCRS. LIMITS In the chromatogram obtained with solution (1): the area of any peak corresponding to (2R)-N-[2-(2-ethoxyphenoxy)ethyl]-1-(4- methoxyphenyl)propan-2-amine is not greater than 2.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.5%); the area of any other secondary peak is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%); the sum of the areas of all secondary peaks is not greater than 7.5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%). Disregard any peak with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.05%). Uniformity of content Capsules containing less than 2 mg and/or less than 2% w/w of Tamsulosin Hydrochloride comply with the requirements stated under Capsules using the following method of analysis. Carry out the method for liquid chromatography, Appendix III D, using the following solutions. (1) Mix the contents of 1 capsule with 10 ml of 1M methanolic hydrochloric acid for at least 15 minutes with the aid of ultrasound and with intermittent shaking, filter through a 0.7-µm glass fibre filter, dilute 1 volume of the filtrate to 10 volumes with 1M methanolic hydrochloric acid and filter through a 0.7-µm glass fibre filter. (2) Prepare a 0.040% w/v solution of tamsulosin hydrochloride BPCRS in methanol with the aid of ultrasound, cool and dilute 1 volume to 100 volumes with 1M methanolic hydrochloric acid . CHROMATOGRAPHIC CONDITIONS The chromatographic conditions described under Related substances may be used. DETERMINATION OF CONTENT Calculate the content of CHNOS,HCl in each capsule from the declared content of CHNOS,HCl in 202825202825tamsulosin hydrochloride BPCRS. ASSAY Carry out the method for liquid chromatography, Appendix III D, using the following freshly prepared solutions. (1) To a quantity of the powdered mixed contents of 20 capsules containing 1.6 mg of Tamsulosin Hydrochloride add 50 ml of 1M methanolic hydrochloric acid , mix for at least 15 minutes with the aid of ultrasound, cool and add sufficient 1M methanolic hydrochloric acid to produce 100 ml. Filter using a 0.7-µm glass fibre filter and dilute 1 volume of the filtrate to 4 volumes with 0.1M methanolic hydrochloric acid . (2) Prepare a 0.040% w/v solution of tamsulosin hydrochloride BPCRS in methanol with the aid of ultrasound, cool and dilute 1 volume to 100 volumes with 1M methanolic hydrochloric acid . CHROMATOGRAPHIC CONDITIONS The chromatographic conditions described under Related substances may be used. DETERMINATION OF CONTENT Calculate the content of CHNOS,HCl in the capsules from the declared content of CHNOS,HCl in 202825202825tamsulosin hydrochloride BPCRS. STORAGE Prolonged-release Tamsulosin Capsules should be protected from moisture. IMPURITIES The impurities limited by the requirements of this monograph include impurities B, E, F and H listed under the Tamsulosin Hydrochloride monograph.